Vistagen Therapeutics, Inc. Share Price & Technical Analysis
VTGN · $0.56 (-3.45%)
Healthcare / Biotechnology
$0.56
-3.45%
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odo…
Price chart
Seasonality
Jun has 0 positive and 4 negative years (last 5 years shown)
0% return in Jun, -28% avg return in past 3 year Jun month.
-14% return in 2026, 55% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 0% | 0% | 0% | 0% | 0% | – | – | – | – | – | – | -14% |
| 25 | -3% | -4% | -7% | -8% | 13% | -20% | 45% | 18% | 6% | 11% | 17% | -86% | -18% |
| 24 | -6% | 4% | 4% | -11% | -19% | -10% | -3% | 3% | -14% | 3% | -10% | 3% | -55% |
| 23 | 136% | -31% | -33% | 8% | 0% | -55% | 0% | 194% | 0% | -35% | 13% | 42% | 239% |
| 22 | -17% | -14% | -11% | 3% | -8% | -23% | -84% | 29% | -12% | -13% | 8% | -29% | -171% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$23.13M
P/E ratio
—
52W high
$5.14
52W low
$0.43
Volume
5,68,959
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Vistagen Therapeutics, Inc. share price today?
- Vistagen Therapeutics, Inc. (VTGN) last traded around $0.56 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VTGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VTGN. Download the app for real-time alerts.
- How can I analyze Vistagen Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.